Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.58 |
| ▸ | NPY4R | P50391 | 8/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.58 |
| ▸ | NPY1R | P25929 | 6/20 | 0.58 |
| ▸ | TFPI | P10646 | 4/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.54 |
| ▸ | RAMP3 | O60896 | 4/20 | 0.54 |
| ▸ | CALCR | P30988 | 4/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | KDM5A | P29375 | 1/20 | 0.53 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.53 |
| ▸ | EP300 | Q09472 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30429252 | 0.89 | NPY2R (0.64) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| Qatvgdvntdrpglldlk SCHEMBL30399126 | 0.89 | NPY2R (0.60) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30906350 | 0.89 | NPY2R (0.59) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30175378 | 0.89 | RAMP3 (0.56) | NPY2RNPY4RNPY5RNPY1RCXCR4 | |
| SCHEMBL30512553 | 0.89 | KDM1A (0.56) | NPY2RNPY4RNPY5RNPY1RCXCR4 | |
| SCHEMBL30495607 | 0.89 | NPY2R (0.64) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL31182888 | 0.89 | NPY2R (0.63) | NPY2RNPY4RNPY5RNPY1RCXCR4 | |
| SCHEMBL30974402 | 0.88 | NPY2R (0.55) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30844333 | 0.88 | RAMP3 (0.53) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30906413 | 0.88 | NPY2R (0.57) | NPY2RNPY4RNPY5RNPY1RRAMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12318418-B2 | Modified adenoviruses | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2025-06-03 | — | — | US | claimed |
| CN-118834841-A | Modified adenoviruses | 加的夫大学学院咨询有限公司 | 2024-10-25 | — | — | CN | claimed |
| US-12054714-B2 | Peptide docking vehicle for targeted nucleic acid delivery | SIRNAOMICS, INC. (US) | 2024-08-06 | — | — | US | claimed |
| CN-112020368-B | Modified adenoviruses | 加的夫大学学院咨询有限公司 | 2024-07-12 | — | — | CN | claimed |
| US-20240180982-A1 | MODIFIED ADENOVIRUS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2024-06-06 | — | — | US | claimed |
| WO-2024074825-A1 | ADENOVIRAL VECTOR THERAPY | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2024-04-11 | — | — | WO | claimed |
| EP-4313093-A1 | MODIFIED ADENOVIRUS | University College Cardiff Consultants LTD. (GB) | 2024-02-07 | — | — | EP | claimed |
| EP-3737403-B1 | MODIFIED ADENOVIRUSES | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2024-01-03 | — | — | EP | claimed |
| US-20230183317-A1 | METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-15 | — | — | US | claimed |
| EP-4146268-A2 | METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS | The Regents of the University of California (US) | 2023-03-15 | — | — | EP | claimed |
| US-20220387599-A1 | OLIGONUCLEOTIDES WITH NUCLEOSIDE ANALOGS | SIRNAOMICS, INC. | 2022-12-08 | — | — | US | claimed |
| EP-4069261-A2 | PEPTIDE DOCKING VEHICLE FOR TARGETED NUCLEIC ACID DELIVERY | Sirnaomics, Inc. (US) | 2022-10-12 | — | — | EP | claimed |
| WO-2022208056-A1 | MODIFIED ADENOVIRUS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-10-06 | — | — | WO | claimed |
| EP-3131566-B1 | BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2022-10-05 | — | — | EP | claimed |
| EP-4038187-A1 | OLIGONUCLEOTIDES WITH NUCLEOSIDE ANALOGS | Sirnaomics, Inc. (US) | 2022-08-10 | — | — | EP | claimed |
| CN-114885604-A | Peptide docking vectors for targeted delivery of nucleic acids | 圣诺制药公司 | 2022-08-09 | — | — | CN | claimed |
| US-20220054645-A1 | Targeted Delivery of Therapeutic Molecules | Zhang, Peter (CN) | 2022-02-24 | — | — | US | claimed |
| EP-4731270-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | The Regents of The University of California (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20220054645-A1 | Targeted Delivery of Therapeutic Molecules | Zhang, Peter (CN) | 2022-02-24 | — | — | US | disclosed |
| EP-3946464-A1 | COMPOUNDS AND CONJUGATES THEREOF | MedImmune Limited (GB) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054645-A1 | Targeted Delivery of Therapeutic Molecules | CD44, CD47, EPCAM | NPY2R 1578/4885NPY4R 1989/4885NPY5R 1778/4885 |
| US-20230183317-A1 | METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS | ACE2, ACE, MAVS | NPY2R 4258/4885NPY4R 4508/4885NPY5R 4491/4885 |
| US-12054714-B2 | Peptide docking vehicle for targeted nucleic acid delivery | SNRPE, RNASE1, CNBP | NPY2R 1762/4885NPY4R 1599/4885NPY5R 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.